【medical-news】【资讯翻译】卡培他滨可提高乳腺癌新辅助治疗pCR
发布于 2014-01-21 · 浏览 989 · IP 陕西陕西
这个帖子发布于 11 年零 114 天前，其中的信息可能已发生改变或有所发展。
认领翻译的战友请跟帖注明“本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领"
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
Increased pCR With Addition of Capecitabine to Epirubicin/Docetaxel in Neoadjuvant Treatment of Breast Cancer
Ann. Oncol 2013 Dec 16;[EPub Ahead of Print], GG Steger, R Greil, A Lang, M Rudas, F Fitzal, B Mlineritsch, BL Hartmann, R Bartsch, E Melbinger, M Hubalek, H Stoeger, P Dubsky, S Ressler, AL Petzer, CF Singer, C Muss, R Jakesz, SP Gampenrieder, CC Zielinski, C Fesl, M Gnant Research · December 26, 2013 TAKE-HOME MESSAGE
This 536-patient trial included all histologic subtypes of breast cancer and found the overall pCR rate increased from 15% to 23% when capecitabine was added to concurrent epirubicin and docetaxel in the neoadjuvant setting.
However, given the multitude of recently reported trials in this setting, it is unclear where this regimen will fit in the overall treatment paradigm.
- Richard Bambury, MD
http://www.practiceupdate.com/journalscan/7333
--------------------------------------------------------------------------------
ABSTRACT
BACKGROUND
This randomized phase III trial compared pathologic complete response (pCR) rates of early breast cancer (EBC) following neoadjuvant epirubicin-docetaxel (ED) ± capecitabine (C), and evaluated the addition of trastuzumab in HER2-positive tumors.
PATIENTS AND METHODS
Patients with invasive breast cancer (except T4d) were randomly assigned to receive six 3-weekly cycles of ED (both 75 mg/m(2)) ± C (1000 mg/m(2), twice daily, days 1-14). Patients with HER2-positive disease were further randomized to receive trastuzumab (8 mg/kg, then 6 mg/kg every 3 weeks) or not. Primary end point: pCR rate at the time of surgery.
RESULTS
Five hundred thirty-six patients were randomized to ED (n = 266) or EDC (n = 270); 93 patients were further randomized to trastuzumab (n = 44) or not (n = 49). pCR rate was significantly increased with EDC (23.0% versus 15.4% ED, P = 0.027), and nonsignificantly further increased with trastuzumab (38.6% EDC versus 26.5% ED, P = 0.212). Rates of axillary node involvement at surgery and breast conservation were improved with EDC versus ED, but not significantly; the addition of trastuzumab had no further impact. Hormone receptor status, tumor size, grade, and C (all P ≤ 0.035) were independent prognostic factors for pCR. Trastuzumab added to ED ± C significantly increased the number of serious adverse events (35 versus 18; P = 0.020), mainly due to infusion-related reactions.
CONCLUSION
These findings show that the integration of C into a neoadjuvant taxane-/anthracycline-based regimen is a feasible, safe, and effective treatment option, with incorporation of trastuzumab in HER2-positive disease.
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
新近参与本次活动的会员请查看：【公告】动态版重启资讯翻译计划：我为人人，人人为我，共同提高
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 【版务】科技动态版版规及加分细则（ 2014-02-21 更新）
Increased pCR With Addition of Capecitabine to Epirubicin/Docetaxel in Neoadjuvant Treatment of Breast Cancer
Ann. Oncol 2013 Dec 16;[EPub Ahead of Print], GG Steger, R Greil, A Lang, M Rudas, F Fitzal, B Mlineritsch, BL Hartmann, R Bartsch, E Melbinger, M Hubalek, H Stoeger, P Dubsky, S Ressler, AL Petzer, CF Singer, C Muss, R Jakesz, SP Gampenrieder, CC Zielinski, C Fesl, M Gnant Research · December 26, 2013 TAKE-HOME MESSAGE
This 536-patient trial included all histologic subtypes of breast cancer and found the overall pCR rate increased from 15% to 23% when capecitabine was added to concurrent epirubicin and docetaxel in the neoadjuvant setting.
However, given the multitude of recently reported trials in this setting, it is unclear where this regimen will fit in the overall treatment paradigm.
- Richard Bambury, MD
http://www.practiceupdate.com/journalscan/7333
--------------------------------------------------------------------------------
ABSTRACT
BACKGROUND
This randomized phase III trial compared pathologic complete response (pCR) rates of early breast cancer (EBC) following neoadjuvant epirubicin-docetaxel (ED) ± capecitabine (C), and evaluated the addition of trastuzumab in HER2-positive tumors.
PATIENTS AND METHODS
Patients with invasive breast cancer (except T4d) were randomly assigned to receive six 3-weekly cycles of ED (both 75 mg/m(2)) ± C (1000 mg/m(2), twice daily, days 1-14). Patients with HER2-positive disease were further randomized to receive trastuzumab (8 mg/kg, then 6 mg/kg every 3 weeks) or not. Primary end point: pCR rate at the time of surgery.
RESULTS
Five hundred thirty-six patients were randomized to ED (n = 266) or EDC (n = 270); 93 patients were further randomized to trastuzumab (n = 44) or not (n = 49). pCR rate was significantly increased with EDC (23.0% versus 15.4% ED, P = 0.027), and nonsignificantly further increased with trastuzumab (38.6% EDC versus 26.5% ED, P = 0.212). Rates of axillary node involvement at surgery and breast conservation were improved with EDC versus ED, but not significantly; the addition of trastuzumab had no further impact. Hormone receptor status, tumor size, grade, and C (all P ≤ 0.035) were independent prognostic factors for pCR. Trastuzumab added to ED ± C significantly increased the number of serious adverse events (35 versus 18; P = 0.020), mainly due to infusion-related reactions.
CONCLUSION
These findings show that the integration of C into a neoadjuvant taxane-/anthracycline-based regimen is a feasible, safe, and effective treatment option, with incorporation of trastuzumab in HER2-positive disease.
最后编辑于 2022-10-09 · 浏览 989
3 1 点赞
